Assessment of Tumor Response in Mice with Ovarian Peritoneal Carcinomatosis using Doppler Ultrasound of the Superior Mesenteric Artery and Celiac Trunk.


Journal

Ultrasound in medicine & biology
ISSN: 1879-291X
Titre abrégé: Ultrasound Med Biol
Pays: England
ID NLM: 0410553

Informations de publication

Date de publication:
03 2021
Historique:
received: 09 05 2020
revised: 22 11 2020
accepted: 29 11 2020
pubmed: 29 12 2020
medline: 27 8 2021
entrez: 28 12 2020
Statut: ppublish

Résumé

The goal of the work described here was to assess the performance of Doppler ultrasound (US) of the superior mesenteric artery (SMA) and celiac trunk (CT) in the evaluation of tumor response in female mice with ovarian peritoneal carcinomatosis treated either with bevacizumab or with carboplatin. Compared with untreated mice, carboplatin-treated mice had a lower weight (23.3 ± 2.0 vs. 27.9 ± 2.9 g, p < 0.001), peritoneal carcinomatosis index (PCI, 11 ± 3 vs. 28 ± 6, p < 0.001), Ki67-positive staining surfaces (p < 0.001), vascular density (p < 0.001), mean blood flow velocity (mBFVel) in the SMA (7.0 ± 1.4 vs. 10.9 ± 1.8 cm/s, p < 0.001) and CT (8.0 ± 1.8 vs. 14.3 ± 4.6 cm/s, p < 0.001) and no ascites. Weight and mBFVel were similar in bevacizumab-treated and untreated mice. The mBFVels in the SMA and CT correlated with the PCI used as an estimation of the tumor burden, R = 0.70 (p < 0.0001) and R = 0.65 (p < 0.0001), respectively. Doppler US allows non-invasive assessment of the effects of anticancer therapy in ovarian peritoneal carcinomatosis-induced mice.

Identifiants

pubmed: 33358050
pii: S0301-5629(20)30539-1
doi: 10.1016/j.ultrasmedbio.2020.11.030
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Bevacizumab 2S9ZZM9Q9V
Carboplatin BG3F62OND5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

759-768

Informations de copyright

Copyright © 2020 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.

Auteurs

Matthias Barral (M)

INSERM Unité 1275 CAP Paris-Tech, Université de Paris, Paris, France.

Cynthia Pimpie (C)

INSERM Unité 1275 CAP Paris-Tech, Université de Paris, Paris, France.

Rachid Kaci (R)

INSERM Unité 1275 CAP Paris-Tech, Université de Paris, Paris, France; Anatomopathologie, hôpital Lariboisière, Université de Paris, Paris, France.

Iman Al-Dybiat (I)

INSERM Unité 1275 CAP Paris-Tech, Université de Paris, Paris, France.

Massoud Mirshahi (M)

INSERM Unité 1275 CAP Paris-Tech, Université de Paris, Paris, France.

Marc Pocard (M)

INSERM Unité 1275 CAP Paris-Tech, Université de Paris, Paris, France; Chirurgie Digestive et cancérologique, hôpital Lariboisière, Université de Paris, Paris, France.

Philippe Bonnin (P)

Physiologie Clinique-Explorations-Fonctionnelles, hopital Lariboisière, Université de Paris, Paris, France; INSERM U1148, LVTS, hôpital Bichat, Université de Paris, Paris, France. Electronic address: philippe.bonnin@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH